Candel Therapeutics Revenue vs. Price To Sales
| CADL Stock | USD 4.71 0.00 0.00% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 31 K | Current Value 29.4 K | Quarterly Volatility 33.3 K |
For Candel Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Candel Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Candel Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Candel Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Candel Therapeutics over time as well as its relative position and ranking within its peers.
Candel |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Candel Therapeutics Price To Sales vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Candel Therapeutics's current stock value. Our valuation model uses many indicators to compare Candel Therapeutics value to that of its competitors to determine the firm's financial worth. Candel Therapeutics is rated fifth in revenue category among its peers. It is number one stock in price to sales category among its peers fabricating about 0.01 of Price To Sales per Revenue. The ratio of Revenue to Price To Sales for Candel Therapeutics is roughly 71.03 . At this time, Candel Therapeutics' Total Revenue is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Candel Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Candel Revenue vs. Competition
Candel Therapeutics is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 26.08 Million. Candel Therapeutics adds roughly 31,000 in revenue claiming only tiny portion of equities under Health Care industry.
Candel Price To Sales vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Candel Therapeutics |
| = | 31 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Candel Therapeutics |
| = | 436.42 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Candel Price To Sales Comparison
Candel Therapeutics is currently under evaluation in price to sales category among its peers.
Candel Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Candel Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Candel Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Candel Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Candel Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -30 K | -28.5 K | |
| Interest Income | 2.1 M | 1.2 M | |
| Operating Income | -38.4 M | -40.3 M | |
| Net Loss | -31.9 M | -33.5 M | |
| Income Before Tax | -37.9 M | -39.8 M | |
| Total Other Income Expense Net | 452 K | 640 K | |
| Net Loss | -16.9 M | -17.8 M | |
| Net Loss | -37.9 M | -39.8 M | |
| Income Tax Expense | -14.3 M | -13.6 M | |
| Non Operating Income Net Other | -9.4 M | -9.8 M | |
| Change To Netincome | -12.4 M | -11.8 M | |
| Net Loss | (1.31) | (1.38) | |
| Income Quality | 0.90 | 0.70 | |
| Net Income Per E B T | 0.18 | 0.17 |
Candel Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Candel Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Candel Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Candel Therapeutics' important profitability drivers and their relationship over time.
Use Candel Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Candel Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will appreciate offsetting losses from the drop in the long position's value.Candel Therapeutics Pair Trading
Candel Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Candel Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Candel Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Candel Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Candel Therapeutics to buy it.
The correlation of Candel Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Candel Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Candel Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Candel Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Candel Therapeutics position
In addition to having Candel Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tips ETFs Thematic Idea Now
Tips ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
To fully project Candel Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Candel Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Candel Therapeutics' income statement, its balance sheet, and the statement of cash flows.